AR
TRIB

Advisory Research’s Trinity Biotech TRIB Stock Holding History

Advisory Research’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-158
Closed -$433K – 346
2014
Q3 		$433K Buy
+158
New +$513K ﹤0.01% 294
2013
Q3 		– Sell
-146
Closed -$370K – 315
2013
Q2 		$370K Buy
+146
New +$363K ﹤0.01% 273

Other funds holding TRIB

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $856M AUM 70.44% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $7.65B AUM 13.87% 1-Year Est. Return

Advisory Research's TRIB Position: Q4 2014 in Review

Advisory Research sold out of Trinity Biotech (TRIB) in Q4 2014, closing a stake of 158 shares — an estimated $433K sold.

Advisory Research first reported a position in TRIB in Q2 2013 and held it in 2 quarters. The position peaked at $433K in Q3 2014. 92 funds tracked by Wall St. Rank hold TRIB as of Q4 2014.

  • Advisory Research reported no remaining Trinity Biotech position as of Q4 2014 after selling out during the quarter.
  • Advisory Research sold 158 Trinity Biotech shares in Q4 2014, an estimated $433K.
  • Advisory Research first reported a position in Trinity Biotech in Q2 2013 and held it in 2 quarters.
  • Advisory Research's Trinity Biotech position peaked at $433K in Q3 2014.
  • 92 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2014.

Based on Advisory Research's 13F filing for Q4 2014, filed 13 Feb 2015.